 |
| Note: For details on a project, click on the title |
A Phase I Multicenter, Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160
Sponsor: NIAID
*
|
A Phase I Multicenter, Randomized, Double-blind, Trial to Evaluate the Safety and Immunogenicity of Recombinant Vaccinia Virus Expressing the Envelope Glycoproteins of Human Immunodeficiency Virus
Sponsor: NIAID
*
|
A Phase I Multicenter, Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160
Sponsor: NIAID
*
|
A Phase I Multicenter, Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160
Sponsor: NIAID
*
|
A Phase I Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination with Soluble Recombinant Envelope Vaccine
Sponsor: NIAID
*
|
A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficinecy Virus at Two Different Vaccination Schedules
Sponsor: NIAID
*
|
A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules
Sponsor: NIAID
*
|
A Phase I Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination with Soluble Recombinant Envelope Vaccine (VaxSyn)
Sponsor: NIAID
*
|
A Phase I Study of the Safety and Immunogenicity og Live Recombinant ALVAC-HIV vCP205 in HIV-1 Uninfected Volunteers in Uganda
Sponsor: NIAID
France
|
No title
Sponsor: WRAIR
France
|
A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternative Mucosal Routes in HIV-1 Unifected Ad
Sponsor: NIAID
France
|
A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 with or without HIV-1 SF-2 RGP-120 in HIV-1 Uninfected Adult
Sponsor: NIAID
France
|
A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP300 and HIV-1 SF-2 rgp120 in HIV-1 Unifected Adult Volunteers
Sponsor: NIAID
France
|
A Phase I Trial to Compare the Safety and Immunogenicity of Three Live Recombinant Canarypox ALVAC-HIV Vaccines vCP205, vCP1433 and vCP1452, in HIV-1 Uninfected Adult Volunteers
Sponsor: NIAID
France
|
A Multisite Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of ALVAC-HIV vCP1452 Alone and Combined with MN rgp120 in Brazil, Haiti, and Trinidad and Tobago
Sponsor: NIH
France
|
A Study of the Effects of Giving Two Anti-HIV Vaccines to Babies of HIV-Positive Mothers
Sponsor: NIAD
France
|
A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 gag-pol DNA Vaccine (APL-400-047, Apollon, Inc.) Given Intramusculary by Needle and Syringe or Biojector 2000 Needle-free Jet Injection System in HIV-1 Unibfected Adult Volunteers
Sponsor: NIAID
France
|
No title
Sponsor: ANRS
France
|
No title
Sponsor: WRAIR
France
|
A Multi-centered, Phase 1 Trial to Evaluate the Memory Responses to a Single Boosting Vaccination with ALVAC-HIV vCP205 in Volunteers Who Have Previously Received Poxvirus-based Vaccines
Sponsor: NIAID
France
|
No title
Sponsor: ANRS
France
|
No title
Sponsor: NIAID
France/United States
|
A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (VCP205) and HIV-1 SF-2 RGP-120 Administered in an Accelerated Sched
Sponsor: NIAID
France/United States
|
A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox-GP 160 MN (ALVAC VCP125, HIV-1 GP160 MN) in HIV-1 Uninfected Adults
Sponsor: NIAID
France/United States
|
A Phase I Safety and Immunogenicity Trial od Live Recombinant Canarypox Alvac-HIV (vCP205) in HIV-1 Unifected Adult Volunteers
Sponsor: NIAID
France/United States
|
A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined with GM-CSF in Healthy, HIV-1 Uninfected Volunteers
Sponsor: NIAID
France/United States
|
A Phase I Trial to Evaluate the HIV-1 SF-2 Recombinant p24 Sununit Vaccine Administered as a Novel Boost in "Prime Boost" Vaccination Regiments with ALVAC-HIV vCP205 (PMC) and HIV-1 SF-2 rgp120 in MF59 (Chiron)
Sponsor: NIAID
France/United States
|
A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects
Sponsor: NIAID
United Kingdom
|
A Phase I, Randomized, Double-Blind, Clinical Trial to Compare the Safety and Immunogenicity or Recombinant Envelope Protein, SF-2 rgp120/HIV-1 (Biocine), Individually Combined with Seven Adjuvants, in Healthy HIV-1 Uninfected Individuals
Sponsor: NIAID
United States
|
No title
Sponsor: NIAID
United States
|
A Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination wit
Sponsor: NIAID
United States
|
No title
Sponsor: NIAID
United States
|
No title
Sponsor: NIAID
United States
|
No title
Sponsor: NIAID
United States
|
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of a Combined Regimen Using ALVAC vCP1452 and AIDSVAX B/B
Sponsor: NIAID
United States
|
A Phase I Multicenter Study of the Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine Given Either Alone or in Combination with IIIB rgp120/HIV-1 Va
Sponsor: NIAID
United States
|
A Phase I Safety and Immunogenicity Study Trial of UBI Microparticulate Monovalent HIV-1 MN Peptide Immunogen in HIV-1 Seronegative Human Subjects
Sponsor: NIAID
United States
|
A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of ENV 2-3 in Combination with MF59
Sponsor: NIAID
United States
|
A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of 200m
Sponsor: NIAID
United States
|
A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus
Sponsor: NIAID
United States
|
A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Env 2-3, a Yeast Derived Envelope Protein of HIV-1, in Combination with MF59/MTP-PE
Sponsor: NIAID
United States
|
A Multicenter, Randomized, Placebo-Controlled, Double-blind Trial to Evaluate the Safety and Immunogenicity of the Therion Recombinant Vaccinia-HIV-1 IIIB env/gag/pol Vaccine (TBC-3B) and MN rgp120/HIV in Alum (VaxGen)
Sponsor: NIAID
United States
|
A Phase III Trial to Determine the Efficacy of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand
Sponsor: VaxGen
United States
|
A Phase III Trial to Determine the Efficacy of Bivalent AIDSVAX B/B Vaccine in Adults at Risk of Sexually Transmitted HIV-1 Infection in North America
Sponsor: VaxGen
United States
|
Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination
Sponsor: NIAID
United States
|
A Phase I Safety and Immunogenicity Trial of HIV-1 gp120 C4-V3 Hybrid Polyvalent Peptide Immunogen Mixed in Mineral Oil Containing Mannose Mono-Oleate (IFA)
Sponsor: NIAID
United States
|
A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV-1 IIIB env/gag/pol Vaccine (TCB-3B)
Sponsor: NIAID
United States
|
No title
Sponsor: Cel-Sci
United States
|
A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine)
Sponsor: NIAID
United States
|
A Phase I Safety and Immunogenicity Trial of UBI Multivalent HIV-1 Peptide Immnogen
Sponsor: NIAID
United States
|
A Phase I Trial to Evaluate the Safety and Immunogenicity of the UBI HIV-1 MN PND Peptide Immunogen, Given by IM Injection, in combination with the UB
Sponsor: NIAID
United States
|
A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Immunotherapeutic in HIV-1 Seronegative Human Subjects
Sponsor: NIAID
United States
|
A Phase I Clinical Trial to Evaluate the Safety of the MF59/MTP-PE Adjuvant Emulsion
Sponsor: NIAID
United States
|
A Phase I Safety and Immunogenicity Trial od Orally Administered Recombinant Salmonella Typhi CVD 908 delta asd (pW57-asd+) Expressing HIV-1 LAI gp120 (VVG 203) and Parenterally Administered HIV-1 MN rgp120 in Alum in HIV-1 Uninfected Volunteers
Sponsor: NIAID
United States
|
No title
Sponsor: VaxGen
United States
|
A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (GP160) of Human Immunodeficiency Virus
Sponsor: NIAID
United States
|
A Phase I Study of the Safety and Immnogenicity of IIIB rgp120/HIV Vaccine in Healthy Adult Subjects
Sponsor: NIAID
United States
|
A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant Subunit HIV-1 Envelope Vaccines SF-2 RGP120 in MF59 (Bi
Sponsor: NIAID - now bivalent
United States
|
A Phase I, Multicenter, Randomized, Double-blind, Controlled HIV-1 Clinical Trial to Evaluate and Compare the Safety and Immunogenicity of MN rgp120/HIV-1 in Combination with QS21 Adjuvant
Sponsor: NIAID
United States
|
A Phase I , Multicenter, Randomized, Double-blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN RSGP 120/HIV-1 in Combination with QS21 Adjuvant or Alum in Healthy Adults
Sponsor: NIAID
United States
|
A Phase I , Multicenter, Randomized, Double-blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN RSGP 120/HIV-1 in Combination with QS21 Adjuvant or Alum in Healthy Adults
Sponsor: NIAID
United States
|
A Phase I, Multicentered, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN RS gp120 and Bivalent AIDSVAX B/E rgp120 in Combination with QS21 with or without Alum in Healthy HIV-1 Uninfected Adults
Sponsor: NIAID
United States
|
A Randomized, Placebo Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120, Combined with MF59
Sponsor: NIAID
United States
|
Phase I/II Trial to Evaluate the Safety and Immunogenicity of AIDSVAX B/B and B/E Vaccines in the United States
Sponsor: VaxGen
United States
|
A double-blind, randomized, placebo-controlled phase I study to evaluate the safety and immunogenicity of a candidate HIV-1 clade A DNA vaccine, p THr-HIV A, delivered intramuscularly by a needle injection in healthy HIV vaccine-naïve HIV-1/2 uninfected a
Sponsor: IAVI
United States/Europe and Central Asia
|
No title
Sponsor: IAVI
United States/Europe and Central Asia
|
An open-label phase I study comparing the safety and immunogenicity of two doses of an HIV-1 clade A DNA vaccine, pTHr.HIVA, delivered by intra-muscular injection to healthy HIV vaccine-naïve HIV-1/2-uninfected adult male and female volunteers.
Sponsor: IAVI
United States/Europe and Central Asia
|
A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adults
Sponsor: NIAID
United States/France
|
Number of Records: 68
|
|
